Press release
Glioma Therapeutic Pipeline Analysis | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm and Key Companies | DelveInsight
Glioma Therapeutic Pipeline
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Download the Sample PDF:
https://www.delveinsight.com/report-store/glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Glioma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights about companies that are developing therapies in the Glioma Market.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and • late-stage of development for Glioma treatment.
• Glioma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Glioma Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF:
https://www.delveinsight.com/report-store/glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Glioma Therapeutics Analysis
There are approx. 150+ key companies which are developing therapies for Glioma. The companies with their Glioma drug candidates in the most advanced stage, i.e. phase II, include, Chimerix.
Some of the key companies in the Glioma Market include:
Chimerix, Sumitomo Dainippon Pharma, AIVITA Biomedical, Denovo Biopharma, Plus Therapeutics, Philogen S.p.A., Xennials Therapeutics, Laminar Pharmaceuticals, Shanghai Gencells Therapeutics, AnHeart Therapeutics Inc., Istari Oncology, Inc., Beijing Pearl Biotechnology Limited Liability Company, Epitopoietic Research Corporation, Everfront Biotech Co., Ltd., CNS Pharmaceuticals, Bexion Pharmaceuticals, Inc., Lee's Pharmaceutical Limited, Merck & Co., Oblato, Inc., OncoSynergy, Inc., SystImmune, Aadi Bioscience, Inc., Day One Biopharmaceuticals, SpringWorks Therapeutics, Inc., Bristol-Myers Squibb, PTC Therapeutics, Apices Soluciones S.L., Chia Tai Tianqing Pharmaceutical, TCRCure Biopharma, SonALAsense, Inc., Midatech Pharma US Inc., Prelude Therapeutics, Incyte Corporation, BioMimetix JV, LLC, GlaxoSmithKline, DNAtrix, Oblato, Inc., NeoImmuneTech, Nuvation Bio Inc., Forma Therapeutics, NanoPharmaceuticals LLC, Erimos Pharmaceuticals, Alaunos Therapeutics, Symphogen, Samus Therapeutics, Inc., Istari Oncology, Neonc Technologies, Inc., Agios Pharmaceuticals, Basilea Pharmaceutica, BeiGene, Kazia Therapeutics, AstraZeneca, Nerviano Medical Sciences, VBL Therapeutics, and many others.
Glioma Therapies covered in the report include:
• ONC 201 (Chimerix)
• DSP-7888 (Sumitomo Dainippon Pharma)
• AV-GBM-1 (AIVITA Biomedical)
• DB102 (Denovo Biopharma)
• AB-218 (AnHeart Therapeutics)
And many more
Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Glioma Current Treatment Patterns
4. Glioma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Glioma Late Stage Products (Phase-III)
7. Glioma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glioma Discontinued Products
13. Glioma Product Profiles
14. Glioma Key Companies
15. Glioma Key Products
16. Dormant and Discontinued Products
17. Glioma Unmet Needs
18. Glioma Future Perspectives
19. Glioma Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at:
https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioma Therapeutic Pipeline Analysis | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm and Key Companies | DelveInsight here
News-ID: 2694597 • Views: …
More Releases from DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments.
The insulin resistance pipeline is broadening with next-generation therapies targeting…
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape.
The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including…
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,…
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment.
The VOC pipeline is diversifying with…
More Releases for Glioma
Glioma Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Glioma Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances…
Glioma Competitive Landscape 2023 (Updated)
DelveInsight's, "Glioma Competitive Landscape 2023" report provides comprehensive insights about 200+ Glioma companies and 220+ drugs in Glioma Competitive landscape. It covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Competitive Landscape Report
• DelveInsight's Glioma report depicts a robust space with 200+ Glioma companies working to develop 220+ pipeline therapies…
Low-Grade Glioma Therapeutics Market - Transforming Futures, Defying Low-Grade G …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Low-Grade Glioma Therapeutics Market.
Low-Grade Glioma Therapeutics Market: https://www.growthplusreports.com/report/lowgrade-glioma-therapeutics-market/9187
The Low-Grade Glioma Therapeutics Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the…
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers…
Glioma pipeline involves 150+ key companies continuously working towards develop …
DelveInsight's, "Glioma Pipeline Insight, 2023," report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Pipeline Report
• DelveInsight's glioma pipeline report depicts a…
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there…
